Polymeric Nanoparticles of Aromatase Inhibitors: A Comprehensive Review | Bentham Science
Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Polymeric Nanoparticles of Aromatase Inhibitors: A Comprehensive Review

Author(s): Keerti Mishra, Pooja Ratre, Suresh Thareja and Akhlesh K. Jain*

Volume 27, Issue 6, 2021

Published on: 29 September, 2020

Page: [855 - 865] Pages: 11

DOI: 10.2174/1381612826666200929123715

Price: $65

Open Access Journals Promotions 2
Abstract

Being the second most frequent cancer, breast cancer is emerging worldwide with an alarming rate, specifically in post-menopausal women. Targeted drug delivery has been in the focus for the successful treatment of breast cancer by enhancing the drug delivery efficiency and reducing the systemic toxicity of drugs. Also, it eliminates the drawbacks associated with conventional chemotherapy, including neuropathy, memory loss, cardiotoxicity and low RBCs count. This review elaborates the polymeric nanoparticles based formulation approaches for selective and sustained delivery for effective cure of breast cancer. However, breast cancer, a life-threatening disease, is mostly caused because of estrogen, thus aromatase inhibitors and estrogen synthesis inhibitors could prevent chances of breast cancer. The disease is associated with drug resistance and some side effects, which could be easily eliminated by using novel therapeutic approaches. Aromatase inhibitors, when entrapped in nanoparticles, have shown sustained drug release, advocating themselves to be beneficial for the treatment of breast cancer.

Keywords: Breast cancer, estrogen, aromatase, aromatase inhibitors, nano drug delivery, nanoparticles.

« Previous Next »
[1]
Chittakath S, Puthamohan VM, Shaheen NK. In vitro anticancer activity of 5′ fluorouracil coated chitosan nanoparticle. Int J Curr Pharm Res 2016; 8(4): 6-8.
[http://dx.doi.org/10.22159/ijcpr.2016v8i4.15267]
[2]
Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther 2018; 3: 7.
[http://dx.doi.org/10.1038/s41392-017-0004-3] [PMID: 29560283]
[3]
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59(4): 225-49.
[http://dx.doi.org/10.3322/caac.20006] [PMID: 19474385]
[4]
Sariego J. Breast cancer in the young patient. Am Surg 2010; 76(12): 1397-400.
[http://dx.doi.org/10.1177/000313481007601226] [PMID: 21265355]
[5]
DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 2016; 66(1): 31-42.
[http://dx.doi.org/10.3322/caac.21320] [PMID: 26513636]
[6]
Khuwaja GA, Abu-Rezq AN. Bimodal breast cancer classification system. Pattern Anal Appl 2004; 7: 235-42.
[7]
Sun YS, Zhao Z, Yang ZN, et al. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci 2017; 13(11): 1387-97.
[http://dx.doi.org/10.7150/ijbs.21635] [PMID: 29209143]
[8]
Bozovic-Spasojevic I, Azambuja E, McCaskill-Stevens W, Dinh P, Cardoso F. Chemoprevention for breast cancer. Cancer Treat Rev 2012; 38(5): 329-39.
[http://dx.doi.org/10.1016/j.ctrv.2011.07.005] [PMID: 21856081]
[9]
Cuzick J, Sestak I, Bonanni B, et al. SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013; 381(9880): 1827-34.
[http://dx.doi.org/10.1016/S0140-6736(13)60140-3] [PMID: 23639488]
[10]
Yang Y, Pan W, Tang X, Wu S, Sun X. A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer. Oncotarget 2017; 8(29): 48362-74.
[http://dx.doi.org/10.18632/oncotarget.16466] [PMID: 28415634]
[11]
Hiscox S, Davies EL, Barrett-Lee P. Aromatase inhibitors in breast cancer. Maturitas 2009; 63(4): 275-9.
[http://dx.doi.org/10.1016/j.maturitas.2009.05.008] [PMID: 19577386]
[12]
Regan MM, Neven P, Giobbie-Hurder A, et al. BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 2011; 12(12): 1101-8.
[http://dx.doi.org/10.1016/S1470-2045(11)70270-4] [PMID: 22018631]
[13]
Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9(1): 45-53.
[http://dx.doi.org/10.1016/S1470-2045(07)70385-6] [PMID: 18083636]
[14]
Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11(12): 1135-41.
[http://dx.doi.org/10.1016/S1470-2045(10)70257-6] [PMID: 21087898]
[15]
Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res 2010; 1(2): 109-26.
[PMID: 22247839]
[16]
Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54(5): 631-51.
[http://dx.doi.org/10.1016/S0169-409X(02)00044-3] [PMID: 12204596]
[17]
Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomed 2007; 3(1): 20-31.
[18]
Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 2015; 200: 138-57.
[http://dx.doi.org/10.1016/j.jconrel.2014.12.030] [PMID: 25545217]
[19]
Gindy ME, Prud’homme RK. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv 2009; 6(8): 865-78.
[http://dx.doi.org/10.1517/17425240902932908] [PMID: 19637974]
[20]
Lee M, Kim SW. Polyethylene glycol-conjugated copolymers for plasmid DNA delivery. Pharm Res 2005; 22(1): 1-10.
[http://dx.doi.org/10.1007/s11095-004-9003-5] [PMID: 15771224]
[21]
Neelesh KS, Harish K. C, D.P. Chatterjee. In-Vitro study of Anastrozole loaded PLGA Nanoparticles for the treatment of Breast Cancer. Int J of Pharm Life Sci 2016; 7(9): 5159-67.
[22]
Kumar A, Sawant KK. Application of multiple regression analysis in optimization of anastrozole-loaded PLGA nanoparticles. J Microencapsul 2013; 1: 1-10.
[PMID: 23883302]
[23]
Shavi GV, Nayak UY, Maliyakkal N, et al. Nanomedicine of anastrozole for breast cancer: Physicochemical evaluation, in vitro cytotoxicity on BT-549 and MCF-7 cell lines and preclinical study on rat model. Life Sci 2015; 141: 143-55.
[http://dx.doi.org/10.1016/j.lfs.2015.09.021] [PMID: 26423561]
[24]
Dey SK, Mandal B, Bhowmik M, et al. Development and in vitro evaluation of Letrozole loaded biodegradable nanoparticles for breast cancer therapy. Braz J Pharm 2009; 45: 585-91.
[http://dx.doi.org/10.1590/S1984-82502009000300025]
[25]
Mondal N, Halder KK, Kamila MM, et al. Preparation, characterization, and biodistribution of letrozole loaded PLGA nanoparticles in Ehrlich Ascites tumor bearing mice. Int J Pharm 2010; 397(1-2): 194-200.
[http://dx.doi.org/10.1016/j.ijpharm.2010.06.049] [PMID: 20609382]
[26]
Agarwal SS, Sharma N. Evaluation of Anticancer Activity of Anastrozole Loaded Nanoparticle on DMBA Induced Breast Carcinoma Model in Mice. Ijppr Human 2017; 8: 60-74.
[27]
Thandapani G, Sudha PN, Florence JAK, et al. Fabrication of letrozole formulation using chitosan nanoparticles through ionic gelation method Int J Biol Macromol 2017.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.01.147]
[28]
Motiei M, Kashanian S. Novel amphiphilic chitosan nanocarriers for sustained oral delivery of hydrophobic drugs. Eur J Pharm Sci 2016; 99: 285-91.
[http://dx.doi.org/10.1016/j.ejps.2016.12.035] [PMID: 28057549]
[29]
Azandaryani AH, Kashanian S, Shahlaei M, Derakhshandeh K, Motiei M, Moradi S. A Comprehensive Physicochemical, In Vitro and Molecular Characterization of Letrozole Incorporated Chitosan-Lipid Nanocomplex. Pharm Res 2019; 36(4): 62.
[http://dx.doi.org/10.1007/s11095-019-2597-4] [PMID: 30850895]
[30]
Wisdom KS, Bhat IA, Kumar P, et al. Fabrication of chitosan nanoparticles loaded with aromatase inhibitors for the advancement of gonadal development in Clarias magur (Hamilton. Aquaculture 2018; 497: 125-33.
[http://dx.doi.org/10.1016/j.aquaculture.2018.07.049]
[31]
Chandran SP, Natarajan SB, Chandraseharan S, et al. Nano drug delivery strategy of 5-fluorouracil for the treatment of colorectal cancer. J Cancer Res Pract 2017; 4: 45-8.
[http://dx.doi.org/10.1016/j.jcrpr.2017.02.002]
[32]
Hemati Azandaryani A, Kashanian S, Derakhshandeh K. Folate Conjugated Hybrid Nanocarrier for Targeted Letrozole Delivery in Breast Cancer Treatment. Pharm Res 2017; 34(12): 2798-808.
[http://dx.doi.org/10.1007/s11095-017-2260-x] [PMID: 29110284]
[33]
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 2009; 71(4): 349-58.
[http://dx.doi.org/10.4103/0250-474X.57282] [PMID: 20502539]
[34]
Nerella A, Basava RD, Aruna DM. Formulation, Optimization and In vitro Characterization of Letrozole Loaded Solid Lipid Nanoparticles. Int J Pharm Sci Drug Res 2014; 6(3): 183-8.
[35]
Sarkar K, Yang H. Encapsulation and extended release of anti-cancer anastrozole by stealth nanoparticles. Drug Deliv 2008; 15(5): 343-6.
[http://dx.doi.org/10.1080/10717540802035343] [PMID: 18763165]
[36]
Alyafee YA, Alaamery M, Bawazeer S, et al. Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines. Int J Nanomedicine 2017; 13: 199-208.
[http://dx.doi.org/10.2147/IJN.S151139] [PMID: 29343958]
[37]
Alemrayat B, Elhissi A, Husam MY. Preparation and characterization of letrozole-loaded poly(d,l-lactide) nanoparticles for drug delivery in breast cancer therapy. Pharm Dev Technol 2019; 24(2): 235-42.
[PMID: 29561210]

Rights & Permissions Print Cite
Article Metrics
25
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy